Roche closes on EU approval for Tecentriq in breast cancer

Roche closes on EU approval for Tecentriq in breast cancer

Source: 
Pharmaforum
snippet: 

Roche is heading for EU approval of Tecentriq as first-line therapy for triple-negative breast cancer (TNBC), ahead of its checkpoint inhibitor rivals.